Animal Drug User Fee Act; Public Meeting; Request for Comments, 9571-9575 [E8-3267]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
Description: The Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS), is proposing a data
collection activity as part of the
Exploration of Low-Income Couples’
Decision-Making (CDM) Processes
study. This project will gather important
information that will be useful for
improving social services delivery
approaches for working with
individuals in couple relationships. The
proposed collection will consist of two
elements: (1) Focus groups with lowincome couples; and (2) a telephone
survey and observation of low-income
9571
couples. These data collection efforts
will examine sources of conflict and
assess decision-making processes among
low-income couples—especially in
relation to issues directly addressed by
social service programs (e.g.,
employment, housing).
Respondents: Low-income couples.
ANNUAL BURDEN ESTIMATES
pwalker on PROD1PC71 with NOTICES
Focus Group Discussion .........................................................
Telephone Survey ....................................................................
Home Visit Setup and Administration of Oral History Interview and Decision Payoff Ratings .......................................
Paper Tower Task ...................................................................
Economic Decision Task—Revealed Differences ...................
Interpersonal Conflict Discussion ............................................
Video Recall Task ....................................................................
Estimated Total Annual Burden
Hours: 258.
In compliance with the requirements
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Administration,
Office of Information Services, 370
L’Enfant Promenade, SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. E-mail address:
infocollection@acf.hhs.gov. All requests
should be identified by the title of the
information collection.
The Department specifically requests
comments on (a) whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
Number of
responses per
respondent
Annual number of
respondents
Instrument
1
1
2
.333333
32
27
80
80
80
80
80
1
1
1
1
1
.666666
.5
.25
.25
.83
53
40
20
20
66
BILLING CODE 4184–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0082]
Animal Drug User Fee Act; Public
Meeting; Request for Comments
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
SUMMARY: The Food and Drug
Administration (FDA, the agency) is
publishing proposed recommendations
for the reauthorization of the Animal
Drug User Fee Act of 2003 (ADUFA) for
fiscal years (FY) 2009 to 2013. These
proposed recommendations were
developed after a public meeting with
stakeholders and discussions with
regulated industry. ADUFA, enacted
November 18, 2003, directs FDA to
publish these proposed
recommendations in the Federal
Register; hold a meeting at which the
public may present its views on such
recommendations; and provide a period
of 30 days for the public to provide
written comments on such
recommendations.
Dates and Time: The public meeting
will be held on March 11, 2008, from 1
p.m. to 3:30 p.m.
Location: The public meeting will be
held at 7519 Standish Pl., third floor,
PO 00000
Frm 00056
Estimated annual
burden hours
16
80
Dated: February 12, 2008.
Brendan C. Kelly,
Reports Clearance Officer.
[FR Doc. 08–777 Filed 2–20–08; 8:45 am]
AGENCY:
Average burden
hours per
response
Fmt 4703
Sfmt 4703
rm. A, Rockville, MD 20855. There is
parking near the building. Photo
identification is required to clear
building security.
Contact Person: Roxanne Schweitzer,
Center for Veterinary Medicine (HFV–
10), Food and Drug Administration,
7529 Standish Pl., Rockville, MD 20855,
240–276–9705, FAX: 240–276–9744, email: Roxanne.Schweitzer@fda.hhs.gov.
Registration: To ensure there is
sufficient room we ask that you preregister. Furthermore, to assist us in
scheduling, we ask that you notify us
through the registration process if you
wish to make a public comment at the
meeting. To register, please send an
electronic mail message to
roxanne.schweitzer@fda.hhs.gov by
March 4, 2008. Your e-mail should
include the following information:
Name, Company, Company Address,
Company Telephone Number, and Email Address. You will receive a
confirmation within 2 business days.
FDA also will accept walk-in
registration at the meeting site, but
space is limited, and the agency will
close registration when maximum
seating capacity (approximately 500) is
reached. FDA will try to accommodate
all persons who wish to make a public
comment at the meeting, including
those who register at the meeting site,
however, the time allotted for public
comments may depend on the number
of persons who wish to speak.
Additionally, please notify FDA (see
Contact Person) if you need any special
accommodations (such as wheelchair
access or a sign language interpreter) at
least 7 days in advance.
Comments: To ensure consideration
of your comments regarding these
proposed recommendations, you should
E:\FR\FM\21FEN1.SGM
21FEN1
9572
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
pwalker on PROD1PC71 with NOTICES
submit comments by April 14, 2008.
Interested persons may submit written
or electronic comments to the Division
of Dockets Management (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD
20852. Submit electronic comments to
https://www.regulations.gov. Submit a
single copy of electronic comments or
two paper copies of any mailed
comments, except that individuals may
submit one paper copy. Comments are
to be identified with the docket number
found in brackets in the heading of this
document. Received comments may be
seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
Please note that on January 15, 2008,
the FDA Web site transitioned to the
Federal Dockets Management System
(FDMS). FDMS is a Government-wide,
electronic docket management system.
Electronic submissions will be accepted
by FDA through FDMS only.
SUPPLEMENTARY INFORMATION:
I. Introduction
Section 4 of ADUFA, enacted in 2003
(Public Law 108–130, November 18,
2003), authorized FDA to collect user
fees from regulated industry that were to
be dedicated to expediting the review of
animal drug applications in accordance
with certain performance goals
identified in letters dated November 13,
2003, from the Secretary of Health and
Human Services to the Chairman and
Ranking Minority Member of the Energy
and Commerce Committee of the House
of Representatives and the Chairman
and Ranking Minority Member of the
Health, Education, Labor and Pensions
Committee of the Senate.
Before ADUFA, FDA’s animal drug
review process was unpredictable and
slow. Since the implementation of
ADUFA there has been a significant
improvement in FDA funding for the
process for review of new animal drug
applications (NADA), including
significant investments in infrastructure
and support. ADUFA has enabled FDA
to increase the staff dedicated to the
process of reviewing animal drug
applications since 2003 by about 30
percent. As a result, the process for
review of NADAs has become more
predictable and faster.
Under ADUFA, the industry provides
user fees that are available to FDA, in
addition to appropriated funds, to spend
on the animal drug review process.
Moreover, FDA authority to collect user
fees is ‘‘triggered’’ only when a base
amount of appropriated funds, adjusted
for inflation, is spent.
As part of ADUFA, FDA established
review performance goals that have
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
been phased in over a 5 year period.
These performance goals run from FY
2004 through FY 2008 and are intended
to achieve progressive, yearly
improvements in the time for review of
animal drug applications. FDA agreed to
review and act on submissions within
shorter periods of time each fiscal year.
With the fifth and final year of ADUFA
ending on September 30, 2008, FDA has
agreed to review and act on 90 percent
of the following submission types
within specified times:
• Animal drug applications and
reactivations of such applications
within 180 days after submission date.
• Non-manufacturing supplemental
animal drug applications (that is,
supplemental animal drug applications
for which safety or effectiveness data are
required) and reactivations of such
supplemental applications within 180
days after submission date.
• Manufacturing supplemental
animal drug applications and
reactivations of such supplemental
applications within 120 days after
submission date.
• Investigational animal drug study
submissions within 180 days after
submission date.
• Investigational animal drug
submissions consisting of protocols, that
FDA and the sponsor consider to be an
essential part of making the decision to
approve or not approve an animal drug
application or supplemental animal
drug application, without substantial
data, within 60 days after submission
date.
• Administrative animal drug
applications submitted after all
scientific decisions have been made in
the investigational animal drug process
(that is, prior to submission of the
animal drug application) within 60 days
after submission date.
We began public consultation on
ADUFA reauthorization with a public
meeting held on April 24, 2007. The
meeting included presentations by FDA
and four speakers from the public. FDA
presented information on ADUFA’s
successful performance and financial
outcomes. The public participants
represented different stakeholder
groups, including consumer groups and
regulated industry. The stakeholders
were asked to respond to the following
questions: (1) What is your assessment
of the overall performance of the
ADUFA program thus far and (2) What
suggestions or changes would you make
relative to the reauthorization of
ADUFA? There was general agreement
among the responding stakeholders that
ADUFA should be reauthorized. In
preparing proposed recommendations
for ADUFA reauthorization (ADUFA II),
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
FDA has also conducted technical
discussions with regulated industry.
Congress also directed FDA to: (1)
Publish in the Federal Register the
proposed recommendations developed
through this process after negotiations
with the regulated industry, (2) present
the proposed recommendations to the
congressional committees specified in
the statute, (3) hold a public meeting at
which the public can present its views
on the proposed recommendations, and
(4) provide a period of 30 days for the
public to provide written comment on
the proposed recommendations.
We have now concluded discussions
with industry and other stakeholders
regarding reauthorization of ADUFA.
The purpose of this document is to
publish the recommendations FDA
intends to propose to Congress and
announce the dates for the upcoming
public meeting and written comment
period. After the public meeting and the
close of the 30-day comment period,
FDA plans to undertake a careful review
of all public comments on these
proposed recommendations.
II. What FDA is Proposing to
Recommend for ADUFA II
For ADUFA II, as described in the
following paragraphs, FDA plans to
carry forward the performance goals
from ADUFA and to propose additional
goals related to proposed enhancements
to the program. Proposed
recommendations fall into three
categories:
A. Proposals to Ensure Sound
Financial Footing for the Animal Drug
Review Program
B. Proposals to Enhance the Process
for Review of Animal Drug Applications
and
C. Improving the Information
Technology (IT) Infrastructure for
Animal Drug Review
A. Proposed Recommendations to
Ensure Sound Financial Footing
Although user fees have provided
substantial resources to FDA since the
beginning of the program, user fees have
not kept up with the increasing costs of
the program associated with inflation in
pay and benefit costs to the agency, and
rent and rent-related costs. FDA has
experienced an increase in costs of pay
and benefits averaging 5.9 percent per
year over the most recent 5 years. Nonsalary costs, including the costs of rent
and contract support, have also
increased at the same rate. FDA is
proposing changes to the financial
provisions of ADUFA to address these
shortcomings and place the program on
sound financial footing so FDA can
E:\FR\FM\21FEN1.SGM
21FEN1
9573
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
continue with the program and enhance
it.
1. The Proposals Set the Total Fee
Revenue Amounts in Section 740(b) of
the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 379j–12(b)) to
Assure That the Amounts Grow
Sufficiently Each Year to Cover FDA’s
Anticipated Change in Costs Each Year
Based on an analysis of FDA’s recent
costs history and anticipated costs over
the next 5 years, FDA expects the trend
of increasing costs to continue. FDA’s
proposed recommendation to Congress,
after consultation with regulated
industry, is that the total fee revenue
estimate for each of the 5 fiscal years of
ADUFA II be the amounts set out in
table 1 of this document.
TABLE 1.— ADUFA II FEE REVENUE TARGETS FOR EACH YEAR BEGINNING FY 2009
Fiscal Year
2009
2010
Total Revenue Target
$15,260,000
$17,280,000
With this level of proposed funding,
FDA can have confidence that it will
have a stable review workforce over the
5 years to be covered by ADUFA II. That
assurance of a stable animal drug review
workforce enables FDA to commit to a
continuation of the FY 2008
performance goals, and to some
additional performance goals.
2. Proposed Elimination of the Inflation
Adjustment Applied to User Fees
Because the proposed total fee
revenue amounts already have the costs
of inflation built into them, there is no
need for the inflation adjustment that
was applied to the total revenue
amounts that were in ADUFA.
Accordingly, FDA proposes to eliminate
the inflation adjustment provisions for
the fee revenue amounts.
pwalker on PROD1PC71 with NOTICES
3. Technical Changes to Increase
Administrative Efficiency of the User
Fee Program
FDA is proposing several technical
changes to ADUFA to clarify the
original intent of several ADUFA
definitions and to remove potential
ambiguity. FDA’s analysis of the impact
of these changes indicates that they
would be revenue-neutral and would
have a minimal impact on industry feepayers. These technical proposals
include the following:
• Change the date for the calculation
of the inflationary adjustment factor so
it can be calculated before the
President’s budget is sent to Congress;
• Amend the definition of ‘‘animal
drug sponsor’’ to clarify that it includes
a holder of an approved application for
an animal drug that is not marketed but
the application has not been withdrawn;
• Add the definition of ‘‘person’’ to
include affiliates, which continues the
current interpretation of the act and
parallels recent changes made to
Prescription Drug User Fee Act;
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
2011
2012
2013
Total
$19,448,000
$21,768,000
$24,244,000
$98,000,000
• Change the application fee rate for
combination applications subject to the
criteria of section 512(d)(4) of act (21
U.S.C. 360b(d)(4)) (Animal Drug
Availability Act combinations) to onehalf the full application fee rate;
• Delay offsets for collections in
excess of appropriations in any year to
the final year of the ADUFA program
and make offsetting reductions only if
cumulative fees collected over the first
4 years exceed cumulative
appropriations for fees over the same
period; and
• Revise the authorization of
appropriations in the act to match the
total fee revenue amounts being
proposed.
4. Triggers
ADUFA has three triggers. One is tied
to appropriations for the process for
review of new animal drug applications
and two are tied to agency
appropriations. FDA is proposing to
leave the current triggers unchanged
through ADUFA II. The three triggers
are as follows:
(1) Fees may not be assessed for a FY
beginning after FY 2003 unless
appropriations for salaries and expenses
of FDA for such FY (excluding the
amount of fees appropriated for such
FY) are equal to or greater than the
amount of appropriations for the
salaries and expenses of FDA for FY
2003 (excluding the amount of fees
appropriated for such FY) multiplied by
the adjustment factor applicable to the
FY involved.
(2) The fees authorized shall only be
collected and available to defray
increases in the cost of the resources
allocated for the process for the review
of animal drug applications (including
increases in such costs for an additional
number of full-time equivalent positions
in the Department of Health and Human
Services to be engaged in such process)
over such costs, excluding costs paid
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
from fees collected for FY 2003
multiplied by the adjustment factor.
(3) The fees authorized by this section
shall be retained in each FY in an
amount not to exceed the amount
specified in appropriation acts, or
otherwise made available for obligations
for such FY.
B. Enhancing the Process for Premarket
Review
We are proposing changes to the
performance goals that ADUFA
established to enhance the process for
review of animal drug applications. In
addition to the performance goals
established by ADUFA for the review of
administrative animal drug applications
submitted after all scientific decisions
have been made in the investigational
animal drug process (that is, prior to
submission of the animal drug
application) and the review of
manufacturing supplemental animal
drug applications and reactivations of
such supplemental applications, FDA
has agreed to revised performance goals
for the following submission types:
(1) The agency will review and act on
90 percent of non-administrative animal
drug applications and reactivations of
such applications within:
• 180 days after the submission date
(Day 180) if the agency determines
that the application is complete or
incomplete. An application is
incomplete if it would require
substantial data or information to
enable the agency to complete a
comprehensive review of the
application and reach a decision on
the approvability of the application;
or
• 220 days after the submission date
if the agency determines that the
submission of additional nonsubstantial data or information
would likely complete the
application and electronically
requests an end-review amendment
E:\FR\FM\21FEN1.SGM
21FEN1
pwalker on PROD1PC71 with NOTICES
9574
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
to the application on or before Day
180, but the sponsor fails to file
such amendment on or before Day
210. If a sponsor files an
amendment after Day 210, then the
amendment is ineligible for
consideration as an end-review
amendment, the extended
performance goal (345 days) will
not apply, and a complete action
letter will be issued by Day 220 for
the original application; or
• 345 days after the submission date
if the agency electronically requests
an end-review amendment to the
application on or before Day 180
and the sponsor files an end-review
amendment on or before Day 210.
(2) The agency will review and act on
90 percent of non-manufacturing
supplemental animal drug applications
(i.e., supplemental animal drug
applications for which safety or
effectiveness data are required) and
reactivations of such supplemental
applications within:
• 180 days after the submission date
(Day 180) if the agency determines
that the application is complete or
incomplete. An application is
incomplete if it would require
substantial data or information to
enable the agency to complete a
comprehensive review of the
application and reach a decision on
the approvability of the application;
or
• 220 days after the submission date
if the agency determines that the
submission of additional nonsubstantial data or information
would likely complete the
application and electronically
requests an end-review amendment
to the application on or before Day
180, but the sponsor fails to file
such amendment on or before Day
210. If a sponsor files an
amendment after Day 210, then the
amendment is ineligible for
consideration as an end-review
amendment, the extended
performance goal (345 days) will
not apply, and a complete action
letter will be issued by Day 220 for
the original application; or
• 345 days after the submission date
if the agency electronically requests
an end-review amendment to the
application on or before Day 180
and the sponsor files an end-review
amendment on or before Day 210.
(3) The agency will review and act on
90 percent of investigational animal
drug study submissions within:
• 180 days after the submission date
(Day 180) if the agency determines
that the submission is complete or
incomplete. A submission is
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
incomplete if it would require
substantial data or information to
enable the agency to complete a
comprehensive review of the study
submission and reach a decision on
the issue(s) presented in the
submission; or
• 220 days after the submission date
if the agency determines that the
submission of additional nonsubstantial data or information
would likely complete the
submission and electronically
requests an end-review amendment
to the submission on or before Day
180, but the sponsor fails to submit
such amendment on or before Day
210. If a sponsor submits an
amendment after Day 210, then the
amendment is ineligible for
consideration as an end-review
amendment, the extended
performance goal (270 days) will
not apply, and a complete action
letter will be issued by Day 220 for
the original submission; or
• 270 days after the submission date
if the agency electronically requests
an end-review amendment to the
submission on or before Day 180
and the sponsor submits an endreview amendment on or before Day
210.
(4) Review and act on 90 percent of
investigational animal drug submissions
consisting of protocols without
substantial data, that the agency and the
sponsor consider to be an essential part
of the basis for making the decision to
approve or not approve an animal drug
application or supplemental animal
drug application, within:
• 60 days after the submission date
(Day 60) if the agency does not
request an end-review amendment
to the protocol and the agency
determines that the protocol is
acceptable, the agency will notify
the sponsor of this decision
electronically on or before Day 50,
followed by a complete action
letter; or
• 60 days after the submission date
(Day 60) if the agency does not
request an end-review amendment
to the protocol and the agency
determines that a protocol is not
acceptable, the agency will notify
the sponsor of this decision
electronically, providing
preliminary broad areas of protocol
deficiency, on or before Day 50,
with the subsequently issued
complete action letter providing the
detailed protocol assessment. The
sponsor may contact the agency for
a brief clarification of these areas of
deficiency prior to the issuance of
the complete action letter; or
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
• 75 days after the submission date if
the agency electronically requests
an end-review amendment to the
protocol on or before Day 50, but
the sponsor fails to submit such
amendment within 10 days of the
amendment request date. If a
sponsor files an amendment more
than 10 days after the amendment
request date, then the amendment is
ineligible for consideration as an
end-review amendment, the
extended performance goal (refer to
the following paragraph) will not
apply, and a complete action letter
will be issued by Day 75 for the
original submission; or
• The greater of 60 days after the
original protocol is received by the
agency or 20 days after the
amended protocol is received by the
agency if the agency electronically
requests an end-review amendment
on or before Day 50 and the sponsor
submits such amendment within 10
days of the date the amendment is
requested.
(5) The following are additional
efforts related to the performance goals
for all submission types being proposed
for ADUFA II to enhance the premarket
review of animal drug applications:
• The agency and regulated industry
agree to participate in 10 public
workshops by the end of FY 2013
on mutually agreed-upon topics;
• To improve the timeliness and
predictability of foreign
preapproval inspections (PAIs),
sponsors may voluntarily submit at
the beginning of the calendar year,
a list of foreign manufacturing
facilities that are subjects of animal
drug applications, supplemental
animal drug applications, or
investigational animal drug
submissions and may be subject to
foreign PAIs for the following fiscal
year;
• If such a list is voluntarily
submitted the sponsor should
submit a notification 30 days prior
to submitting an animal drug
application, a supplemental animal
drug application, or investigational
animal drug submission that
informs the agency that the
application includes a foreign
manufacturing facility; (should any
changes to the annual list occur
after its submission to the agency,
the sponsor may provide the
updated information to the agency);
• The agency and the regulated
industry agree to explore and
discuss the applicable use of
pharmacokinetic/pharmacodynamic
data in the development and
evaluation of new animal drugs
E:\FR\FM\21FEN1.SGM
21FEN1
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
submitted for approval;
• The agency and the regulated
industry agree to explore
opportunities for exchange of
information regarding the
characteristics of a new animal
drug, and to identify safety and
effectiveness issues as early as
possible in the drug development
process; and
• The agency and regulated industry
commit to work together to explore
shorter timeframes commensurate
with the magnitude of submitted
pharmacokinetic/pharmacodynamic
and other new animal drug
characteristic data/information.
C. Improving the Information
Technology (IT) Infrastructure for
Animal Drug Review
In the recommended IT performance
goals for ADUFA II, FDA will develop
an electronic submission tool for
industry submissions and online review
capability within 24 months of
appropriated ADUFA funds for FY
2009. The agency will consult with the
sponsors in the development of this
tool.
III. What Information Should You
Know About the Meeting?
A. When and Where Will the Meeting
Occur? What Format Will FDA Use?
Through this document, FDA is
announcing the convening of a public
meeting to hear stakeholder views on
the recommendations we propose to
provide to Congress on the
reauthorization of ADUFA.
FDA will conduct the meeting at 1
p.m. on March 11, 2008, at 7519
Standish Pl., third floor, rm. A,
Rockville, MD 20855. In general, the
meeting format will include
presentations by FDA and an open
comment period for the public. FDA
will also give organizations and
individuals an opportunity to submit
written comments to the docket after the
meeting.
pwalker on PROD1PC71 with NOTICES
B. Will Meeting Transcripts Be
Available?
16:34 Feb 20, 2008
Jkt 214001
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0081 (formerly
Docket No. 2006D–0297)]
International Conference on
Harmonisation; Guidance on Q4B
Evaluation and Recommendation of
Pharmacopoeial Texts for Use in the
International Conference on
Harmonisation Regions; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled ‘‘Q4B
Evaluation and Recommendation of
Pharmacopoeial Texts for Use in the
ICH Regions.’’ The guidance was
prepared under the auspices of the
International Conference on
Harmonisation of Technical
Requirements for Registration of
Pharmaceuticals for Human Use (ICH).
The guidance describes a process for the
evaluation and recommendation by the
ICH Q4B Expert Working Group (EWG)
of selected pharmacopeial texts to
facilitate their recognition by regulatory
authorities for use as interchangeable in
the ICH regions. Following favorable
evaluations, ICH will issue topicspecific annexes with information about
these texts and their implementation
(the Q4B Outcomes). Implementation of
the Q4B annexes is intended to avoid
redundant testing by industry in favor of
a common testing strategy in each ICH
regulatory region.
DATES: Submit written or electronic
comments on agency guidances at any
time.
Submit written requests for
single copies of this guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, or the Office of
Communication, Training and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
Rockville, MD 20852–1448. The
guidance may also be obtained by mail
ADDRESSES:
FDA will prepare a meeting transcript
and make it available on the agency’s
Web site (www.fda.gov) after the
meeting. FDA anticipates that
transcripts will be available
approximately 30 business days after
the meeting.The transcript will also be
available for public examination at the
Division of Dockets Management (HFA–
305), 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852, between 9 a.m.
and 4 p.m., Monday through Friday.
VerDate Aug<31>2005
Dated: February 14, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8–3267 Filed 2–20–08; 8:45 am]
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
9575
by calling CBER at 1–800–835–4709 or
301–827–1800. Send two self-addressed
adhesive labels to assist the office in
processing your requests. Submit
written comments on the guidance to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: Robert H.
King, Sr., Center for Drug
Evaluation and Research (HFD–
003), Food and Drug
Administration, 10903 New
Hampshire Ave., Bldg. 21, rm. 3542,
Silver Spring, MD 20993–0002,
301–796–1242;or
Christopher Joneckis, Center for
Biologics Evaluation and Research
(HFM–20), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852–1448,
301–435–5681.
Regarding the ICH: Michelle Limoli,
Office of International Programs
(HFG–1), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–
4480.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a guidance entitled ‘‘Q4B Evaluation
and Recommendation of
Pharmacopoeial Texts for Use in the
ICH Regions.’’ In recent years, many
important initiatives have been
undertaken by regulatory authorities
and industry associations to promote
international harmonization of
regulatory requirements. FDA has
participated in many meetings designed
to enhance harmonization and is
committed to seeking scientifically
based harmonized technical procedures
for pharmaceutical development. One of
the goals of harmonization is to identify
and then reduce differences in technical
requirements for drug development
among regulatory agencies.
ICH was organized to provide an
opportunity for tripartite harmonization
initiatives to be developed with input
from both regulatory and industry
representatives. FDA also seeks input
from consumer representatives and
others. ICH is concerned with
harmonization of technical
requirements for the registration of
pharmaceutical products among three
regions: The European Union, Japan,
E:\FR\FM\21FEN1.SGM
21FEN1
]]>Agencies
[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Pages 9571-9575]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-3267]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0082]
Animal Drug User Fee Act; Public Meeting; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the agency) is
publishing proposed recommendations for the reauthorization of the
Animal Drug User Fee Act of 2003 (ADUFA) for fiscal years (FY) 2009 to
2013. These proposed recommendations were developed after a public
meeting with stakeholders and discussions with regulated industry.
ADUFA, enacted November 18, 2003, directs FDA to publish these proposed
recommendations in the Federal Register; hold a meeting at which the
public may present its views on such recommendations; and provide a
period of 30 days for the public to provide written comments on such
recommendations.
Dates and Time: The public meeting will be held on March 11, 2008,
from 1 p.m. to 3:30 p.m.
Location: The public meeting will be held at 7519 Standish Pl.,
third floor, rm. A, Rockville, MD 20855. There is parking near the
building. Photo identification is required to clear building security.
Contact Person: Roxanne Schweitzer, Center for Veterinary Medicine
(HFV-10), Food and Drug Administration, 7529 Standish Pl., Rockville,
MD 20855, 240-276-9705, FAX: 240-276-9744, e-mail:
Roxanne.Schweitzer@fda.hhs.gov.
Registration: To ensure there is sufficient room we ask that you
pre-register. Furthermore, to assist us in scheduling, we ask that you
notify us through the registration process if you wish to make a public
comment at the meeting. To register, please send an electronic mail
message to roxanne.schweitzer@fda.hhs.gov by March 4, 2008. Your e-mail
should include the following information: Name, Company, Company
Address, Company Telephone Number, and E-mail Address. You will receive
a confirmation within 2 business days.
FDA also will accept walk-in registration at the meeting site, but
space is limited, and the agency will close registration when maximum
seating capacity (approximately 500) is reached. FDA will try to
accommodate all persons who wish to make a public comment at the
meeting, including those who register at the meeting site, however, the
time allotted for public comments may depend on the number of persons
who wish to speak.
Additionally, please notify FDA (see Contact Person) if you need
any special accommodations (such as wheelchair access or a sign
language interpreter) at least 7 days in advance.
Comments: To ensure consideration of your comments regarding these
proposed recommendations, you should
[[Page 9572]]
submit comments by April 14, 2008. Interested persons may submit
written or electronic comments to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Submit electronic comments to https://
www.regulations.gov. Submit a single copy of electronic comments or two
paper copies of any mailed comments, except that individuals may submit
one paper copy. Comments are to be identified with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday.
Please note that on January 15, 2008, the FDA Web site transitioned
to the Federal Dockets Management System (FDMS). FDMS is a Government-
wide, electronic docket management system. Electronic submissions will
be accepted by FDA through FDMS only.
SUPPLEMENTARY INFORMATION:
I. Introduction
Section 4 of ADUFA, enacted in 2003 (Public Law 108-130, November
18, 2003), authorized FDA to collect user fees from regulated industry
that were to be dedicated to expediting the review of animal drug
applications in accordance with certain performance goals identified in
letters dated November 13, 2003, from the Secretary of Health and Human
Services to the Chairman and Ranking Minority Member of the Energy and
Commerce Committee of the House of Representatives and the Chairman and
Ranking Minority Member of the Health, Education, Labor and Pensions
Committee of the Senate.
Before ADUFA, FDA's animal drug review process was unpredictable
and slow. Since the implementation of ADUFA there has been a
significant improvement in FDA funding for the process for review of
new animal drug applications (NADA), including significant investments
in infrastructure and support. ADUFA has enabled FDA to increase the
staff dedicated to the process of reviewing animal drug applications
since 2003 by about 30 percent. As a result, the process for review of
NADAs has become more predictable and faster.
Under ADUFA, the industry provides user fees that are available to
FDA, in addition to appropriated funds, to spend on the animal drug
review process. Moreover, FDA authority to collect user fees is
``triggered'' only when a base amount of appropriated funds, adjusted
for inflation, is spent.
As part of ADUFA, FDA established review performance goals that
have been phased in over a 5 year period. These performance goals run
from FY 2004 through FY 2008 and are intended to achieve progressive,
yearly improvements in the time for review of animal drug applications.
FDA agreed to review and act on submissions within shorter periods of
time each fiscal year. With the fifth and final year of ADUFA ending on
September 30, 2008, FDA has agreed to review and act on 90 percent of
the following submission types within specified times:
Animal drug applications and reactivations of such
applications within 180 days after submission date.
Non-manufacturing supplemental animal drug applications
(that is, supplemental animal drug applications for which safety or
effectiveness data are required) and reactivations of such supplemental
applications within 180 days after submission date.
Manufacturing supplemental animal drug applications and
reactivations of such supplemental applications within 120 days after
submission date.
Investigational animal drug study submissions within 180
days after submission date.
Investigational animal drug submissions consisting of
protocols, that FDA and the sponsor consider to be an essential part of
making the decision to approve or not approve an animal drug
application or supplemental animal drug application, without
substantial data, within 60 days after submission date.
Administrative animal drug applications submitted after
all scientific decisions have been made in the investigational animal
drug process (that is, prior to submission of the animal drug
application) within 60 days after submission date.
We began public consultation on ADUFA reauthorization with a public
meeting held on April 24, 2007. The meeting included presentations by
FDA and four speakers from the public. FDA presented information on
ADUFA's successful performance and financial outcomes. The public
participants represented different stakeholder groups, including
consumer groups and regulated industry. The stakeholders were asked to
respond to the following questions: (1) What is your assessment of the
overall performance of the ADUFA program thus far and (2) What
suggestions or changes would you make relative to the reauthorization
of ADUFA? There was general agreement among the responding stakeholders
that ADUFA should be reauthorized. In preparing proposed
recommendations for ADUFA reauthorization (ADUFA II), FDA has also
conducted technical discussions with regulated industry.
Congress also directed FDA to: (1) Publish in the Federal Register
the proposed recommendations developed through this process after
negotiations with the regulated industry, (2) present the proposed
recommendations to the congressional committees specified in the
statute, (3) hold a public meeting at which the public can present its
views on the proposed recommendations, and (4) provide a period of 30
days for the public to provide written comment on the proposed
recommendations.
We have now concluded discussions with industry and other
stakeholders regarding reauthorization of ADUFA. The purpose of this
document is to publish the recommendations FDA intends to propose to
Congress and announce the dates for the upcoming public meeting and
written comment period. After the public meeting and the close of the
30-day comment period, FDA plans to undertake a careful review of all
public comments on these proposed recommendations.
II. What FDA is Proposing to Recommend for ADUFA II
For ADUFA II, as described in the following paragraphs, FDA plans
to carry forward the performance goals from ADUFA and to propose
additional goals related to proposed enhancements to the program.
Proposed recommendations fall into three categories:
A. Proposals to Ensure Sound Financial Footing for the Animal Drug
Review Program
B. Proposals to Enhance the Process for Review of Animal Drug
Applications and
C. Improving the Information Technology (IT) Infrastructure for
Animal Drug Review
A. Proposed Recommendations to Ensure Sound Financial Footing
Although user fees have provided substantial resources to FDA since
the beginning of the program, user fees have not kept up with the
increasing costs of the program associated with inflation in pay and
benefit costs to the agency, and rent and rent-related costs. FDA has
experienced an increase in costs of pay and benefits averaging 5.9
percent per year over the most recent 5 years. Non-salary costs,
including the costs of rent and contract support, have also increased
at the same rate. FDA is proposing changes to the financial provisions
of ADUFA to address these shortcomings and place the program on sound
financial footing so FDA can
[[Page 9573]]
continue with the program and enhance it.
1. The Proposals Set the Total Fee Revenue Amounts in Section 740(b) of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 379j-
12(b)) to Assure That the Amounts Grow Sufficiently Each Year to Cover
FDA's Anticipated Change in Costs Each Year
Based on an analysis of FDA's recent costs history and anticipated
costs over the next 5 years, FDA expects the trend of increasing costs
to continue. FDA's proposed recommendation to Congress, after
consultation with regulated industry, is that the total fee revenue
estimate for each of the 5 fiscal years of ADUFA II be the amounts set
out in table 1 of this document.
Table 1.-- ADUFA II Fee Revenue Targets for Each Year Beginning FY 2009
--------------------------------------------------------------------------------------------------------------------------------------------------------
Fiscal Year 2009 2010 2011 2012 2013 Total
--------------------------------------------------------------------------------------------------------------------------------------------------------
Total Revenue Target $15,260,000 $17,280,000 $19,448,000 $21,768,000 $24,244,000 $98,000,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
With this level of proposed funding, FDA can have confidence that
it will have a stable review workforce over the 5 years to be covered
by ADUFA II. That assurance of a stable animal drug review workforce
enables FDA to commit to a continuation of the FY 2008 performance
goals, and to some additional performance goals.
2. Proposed Elimination of the Inflation Adjustment Applied to User
Fees
Because the proposed total fee revenue amounts already have the
costs of inflation built into them, there is no need for the inflation
adjustment that was applied to the total revenue amounts that were in
ADUFA. Accordingly, FDA proposes to eliminate the inflation adjustment
provisions for the fee revenue amounts.
3. Technical Changes to Increase Administrative Efficiency of the User
Fee Program
FDA is proposing several technical changes to ADUFA to clarify the
original intent of several ADUFA definitions and to remove potential
ambiguity. FDA's analysis of the impact of these changes indicates that
they would be revenue-neutral and would have a minimal impact on
industry fee-payers. These technical proposals include the following:
Change the date for the calculation of the inflationary
adjustment factor so it can be calculated before the President's budget
is sent to Congress;
Amend the definition of ``animal drug sponsor'' to clarify
that it includes a holder of an approved application for an animal drug
that is not marketed but the application has not been withdrawn;
Add the definition of ``person'' to include affiliates,
which continues the current interpretation of the act and parallels
recent changes made to Prescription Drug User Fee Act;
Change the application fee rate for combination
applications subject to the criteria of section 512(d)(4) of act (21
U.S.C. 360b(d)(4)) (Animal Drug Availability Act combinations) to one-
half the full application fee rate;
Delay offsets for collections in excess of appropriations
in any year to the final year of the ADUFA program and make offsetting
reductions only if cumulative fees collected over the first 4 years
exceed cumulative appropriations for fees over the same period; and
Revise the authorization of appropriations in the act to
match the total fee revenue amounts being proposed.
4. Triggers
ADUFA has three triggers. One is tied to appropriations for the
process for review of new animal drug applications and two are tied to
agency appropriations. FDA is proposing to leave the current triggers
unchanged through ADUFA II. The three triggers are as follows:
(1) Fees may not be assessed for a FY beginning after FY 2003
unless appropriations for salaries and expenses of FDA for such FY
(excluding the amount of fees appropriated for such FY) are equal to or
greater than the amount of appropriations for the salaries and expenses
of FDA for FY 2003 (excluding the amount of fees appropriated for such
FY) multiplied by the adjustment factor applicable to the FY involved.
(2) The fees authorized shall only be collected and available to
defray increases in the cost of the resources allocated for the process
for the review of animal drug applications (including increases in such
costs for an additional number of full-time equivalent positions in the
Department of Health and Human Services to be engaged in such process)
over such costs, excluding costs paid from fees collected for FY 2003
multiplied by the adjustment factor.
(3) The fees authorized by this section shall be retained in each
FY in an amount not to exceed the amount specified in appropriation
acts, or otherwise made available for obligations for such FY.
B. Enhancing the Process for Premarket Review
We are proposing changes to the performance goals that ADUFA
established to enhance the process for review of animal drug
applications. In addition to the performance goals established by ADUFA
for the review of administrative animal drug applications submitted
after all scientific decisions have been made in the investigational
animal drug process (that is, prior to submission of the animal drug
application) and the review of manufacturing supplemental animal drug
applications and reactivations of such supplemental applications, FDA
has agreed to revised performance goals for the following submission
types:
(1) The agency will review and act on 90 percent of non-
administrative animal drug applications and reactivations of such
applications within:
180 days after the submission date (Day 180) if the agency
determines that the application is complete or incomplete. An
application is incomplete if it would require substantial data or
information to enable the agency to complete a comprehensive review of
the application and reach a decision on the approvability of the
application; or
220 days after the submission date if the agency
determines that the submission of additional non-substantial data or
information would likely complete the application and electronically
requests an end-review amendment
[[Page 9574]]
to the application on or before Day 180, but the sponsor fails to file
such amendment on or before Day 210. If a sponsor files an amendment
after Day 210, then the amendment is ineligible for consideration as an
end-review amendment, the extended performance goal (345 days) will not
apply, and a complete action letter will be issued by Day 220 for the
original application; or
345 days after the submission date if the agency
electronically requests an end-review amendment to the application on
or before Day 180 and the sponsor files an end-review amendment on or
before Day 210.
(2) The agency will review and act on 90 percent of non-
manufacturing supplemental animal drug applications (i.e., supplemental
animal drug applications for which safety or effectiveness data are
required) and reactivations of such supplemental applications within:
180 days after the submission date (Day 180) if the agency
determines that the application is complete or incomplete. An
application is incomplete if it would require substantial data or
information to enable the agency to complete a comprehensive review of
the application and reach a decision on the approvability of the
application; or
220 days after the submission date if the agency
determines that the submission of additional non-substantial data or
information would likely complete the application and electronically
requests an end-review amendment to the application on or before Day
180, but the sponsor fails to file such amendment on or before Day 210.
If a sponsor files an amendment after Day 210, then the amendment is
ineligible for consideration as an end-review amendment, the extended
performance goal (345 days) will not apply, and a complete action
letter will be issued by Day 220 for the original application; or
345 days after the submission date if the agency
electronically requests an end-review amendment to the application on
or before Day 180 and the sponsor files an end-review amendment on or
before Day 210.
(3) The agency will review and act on 90 percent of investigational
animal drug study submissions within:
180 days after the submission date (Day 180) if the agency
determines that the submission is complete or incomplete. A submission
is incomplete if it would require substantial data or information to
enable the agency to complete a comprehensive review of the study
submission and reach a decision on the issue(s) presented in the
submission; or
220 days after the submission date if the agency
determines that the submission of additional non-substantial data or
information would likely complete the submission and electronically
requests an end-review amendment to the submission on or before Day
180, but the sponsor fails to submit such amendment on or before Day
210. If a sponsor submits an amendment after Day 210, then the
amendment is ineligible for consideration as an end-review amendment,
the extended performance goal (270 days) will not apply, and a complete
action letter will be issued by Day 220 for the original submission; or
270 days after the submission date if the agency
electronically requests an end-review amendment to the submission on or
before Day 180 and the sponsor submits an end-review amendment on or
before Day 210.
(4) Review and act on 90 percent of investigational animal drug
submissions consisting of protocols without substantial data, that the
agency and the sponsor consider to be an essential part of the basis
for making the decision to approve or not approve an animal drug
application or supplemental animal drug application, within:
60 days after the submission date (Day 60) if the agency
does not request an end-review amendment to the protocol and the agency
determines that the protocol is acceptable, the agency will notify the
sponsor of this decision electronically on or before Day 50, followed
by a complete action letter; or
60 days after the submission date (Day 60) if the agency
does not request an end-review amendment to the protocol and the agency
determines that a protocol is not acceptable, the agency will notify
the sponsor of this decision electronically, providing preliminary
broad areas of protocol deficiency, on or before Day 50, with the
subsequently issued complete action letter providing the detailed
protocol assessment. The sponsor may contact the agency for a brief
clarification of these areas of deficiency prior to the issuance of the
complete action letter; or
75 days after the submission date if the agency
electronically requests an end-review amendment to the protocol on or
before Day 50, but the sponsor fails to submit such amendment within 10
days of the amendment request date. If a sponsor files an amendment
more than 10 days after the amendment request date, then the amendment
is ineligible for consideration as an end-review amendment, the
extended performance goal (refer to the following paragraph) will not
apply, and a complete action letter will be issued by Day 75 for the
original submission; or
The greater of 60 days after the original protocol is
received by the agency or 20 days after the amended protocol is
received by the agency if the agency electronically requests an end-
review amendment on or before Day 50 and the sponsor submits such
amendment within 10 days of the date the amendment is requested.
(5) The following are additional efforts related to the performance
goals for all submission types being proposed for ADUFA II to enhance
the premarket review of animal drug applications:
The agency and regulated industry agree to participate in
10 public workshops by the end of FY 2013 on mutually agreed-upon
topics;
To improve the timeliness and predictability of foreign
preapproval inspections (PAIs), sponsors may voluntarily submit at the
beginning of the calendar year, a list of foreign manufacturing
facilities that are subjects of animal drug applications, supplemental
animal drug applications, or investigational animal drug submissions
and may be subject to foreign PAIs for the following fiscal year;
If such a list is voluntarily submitted the sponsor should
submit a notification 30 days prior to submitting an animal drug
application, a supplemental animal drug application, or investigational
animal drug submission that informs the agency that the application
includes a foreign manufacturing facility; (should any changes to the
annual list occur after its submission to the agency, the sponsor may
provide the updated information to the agency);
The agency and the regulated industry agree to explore and
discuss the applicable use of pharmacokinetic/pharmacodynamic data in
the development and evaluation of new animal drugs
[[Page 9575]]
submitted for approval;
The agency and the regulated industry agree to explore
opportunities for exchange of information regarding the characteristics
of a new animal drug, and to identify safety and effectiveness issues
as early as possible in the drug development process; and
The agency and regulated industry commit to work together
to explore shorter timeframes commensurate with the magnitude of
submitted pharmacokinetic/pharmacodynamic and other new animal drug
characteristic data/information.
C. Improving the Information Technology (IT) Infrastructure for Animal
Drug Review
In the recommended IT performance goals for ADUFA II, FDA will
develop an electronic submission tool for industry submissions and
online review capability within 24 months of appropriated ADUFA funds
for FY 2009. The agency will consult with the sponsors in the
development of this tool.
III. What Information Should You Know About the Meeting?
A. When and Where Will the Meeting Occur? What Format Will FDA Use?
Through this document, FDA is announcing the convening of a public
meeting to hear stakeholder views on the recommendations we propose to
provide to Congress on the reauthorization of ADUFA.
FDA will conduct the meeting at 1 p.m. on March 11, 2008, at 7519
Standish Pl., third floor, rm. A, Rockville, MD 20855. In general, the
meeting format will include presentations by FDA and an open comment
period for the public. FDA will also give organizations and individuals
an opportunity to submit written comments to the docket after the
meeting.
B. Will Meeting Transcripts Be Available?
FDA will prepare a meeting transcript and make it available on the
agency's Web site (www.fda.gov) after the meeting. FDA anticipates that
transcripts will be available approximately 30 business days after the
meeting.The transcript will also be available for public examination at
the Division of Dockets Management (HFA-305), 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through
Friday.
Dated: February 14, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8-3267 Filed 2-20-08; 8:45 am]
BILLING CODE 4160-01-S
